3-picolylcyanoacetamide | 283153-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-picolylcyanoacetamide
• 英文别名: 2-cyano-N-(pyridin-3-ylmethyl)acetamide；2-cyano-N-(3-pyridylmethyl) acetamide
• CAS: 283153-85-5
• 化学式: C₉H₉N₃O
• mdl: MFCD01351849
• 分子量: 175.19
• InChiKey: SYFMQBDZEJECPU-UHFFFAOYSA-N

物化性质

• 熔点：
  50-52°C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-picolylcyanoacetamide 、 7-甲氧基香豆素 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 5-amino-8-methoxy-3-(pyridin-3-ylmethyl)-1H-chromeno[3,4-c]pyridine-2,4(3H,10bH)-dione
  参考文献：
  名称：

  Discovery of chromenes as inhibitors of macrophage migration inhibitory factor

  摘要：

  Macrophage migration inhibitory factor (MIF) is an essential signaling cytokine with a key role in the immune system. Binding of MIF to its molecular targets such as, among others, the cluster of differentiation 74 (CD74) receptor plays a key role in inflammatory diseases and cancer. Therefore, the identification of MIF binding compounds gained importance in drug discovery. In this study, we aim to discover novel MIF binding compounds by screening of a focused compound collection for inhibition of its tautomerase enzyme activity. Inspired by the known chromen-4-one inhibitor Orita-13, a focused collection of compounds with a chromene scaffold was screened for MIF binding. The library was synthesized using versatile cyanoacetamide chemistry to provide diversely substituted chromenes. The screening provided inhibitors with IC50's in the low micromolar range. Kinetic evaluation suggested that the inhibitors were reversible and did not bind in the binding pocket of the substrate. Thus, we discovered novel inhibitors of the MIF tautomerase activity, which may ultimately support the development of novel therapeutic agents against diseases in which MIF is involved. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.12.032
• 作为产物：
  描述：

  3-氨基吡啶 、 氰乙酸甲酯 以 neat (no solvent) 为溶剂， 反应 4.0h， 以96.6%的产率得到3-picolylcyanoacetamide
  参考文献：
  名称：

  吡啶基氰基乙酰胺的过渡金属硫氰酸盐配合物*

  摘要：

  已经合成了多种涉及甲基吡啶基氰基乙酰胺（甲基吡啶= NCCH 2 CONH-R; R = 2-甲基吡啶基-（2pica），3-甲基吡啶基-（3pica），4-甲基吡啶基-（4pica））和硫氰酸盐的过渡金属配合物已经确定了固态结构。络合物全部是由相应的金属盐和皮卡配体与硫氰酸钠在环境条件下的反应获得的。3pica和4pica都仅通过甲基吡啶基的氮原子与金属配位，并形成离散的四面体[M（NCS）2（pica）2 ]（3pica； M = Mn，Zn； 4pica； M = Co）和八面体[ M（NCS）2（3点）4]（M = Co，Fe，Ni）配合物。另外，获得一维N，S-硫氰酸酯桥联的配位聚合物聚-[M（μ-NCS）2（pica）2 ]（3pica； M ＝ Cd； 4pica； M ＝ Co，Cd）。配体2pica给出了离散的八面体络合物[Co（NCS）2（2pica）2 ]和[Cd（NO

  DOI：

  10.1071/ch16648

文献信息

• Modulators of LXR
  申请人：——

  公开号：US20030181420A1

  公开（公告）日：2003-09-25

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节核受体活性的杂环化合物，包括肝X受体（LXR）和孤儿核受体。在某些实施方式中，这些化合物是N-取代吡啶酮。
• X-ray Structure and Molecular Docking Guided Discovery of Novel Chitinase Inhibitors with a Scaffold of Dipyridopyrimidine-3-carboxamide
  作者：Pengtao Yuan、Xi Jiang、Siyu Wang、Xusheng Shao、Qing Yang、Xuhong Qian

  DOI：10.1021/acs.jafc.0c03742

  日期：2020.11.25

  dipyridopyrimidine-3-carboxamide derivatives as chitinase inhibitors. Among them, compound 6t showed the most potent activity against bacterial chitinase SmChiB and insect chitinase OfChi-h, with a Ki value of 0.14 and 0.0056 μM, respectively. The strong stacking interaction of compound 6p with Trp99 and Trp220 found in the SmChiB–6p co-crystal structure verifies the feasibility of our design. Our results provide

  几丁质酶是用于催化几丁质降解的糖基水解酶，在细菌发病机理，真菌细胞壁重塑和昆虫蜕变中起着不可或缺的作用。因此，几丁质酶是治疗药物和杀虫剂的有吸引力的靶标。在这里，我们提出了一种策略，通过构建可以与保守的芳香族残基堆叠的平面杂环，开发一种新型的几丁质酶抑制剂的化学型。通过晶体学分析和对接结果的指导，合理的设计导致了一系列作为几丁质酶抑制剂的二吡啶并嘧啶-3-羧酰胺衍生物。其中，化合物6吨表现出抗细菌几丁质酶的最有效的活性的Sm奇夫和昆虫几丁质酶中驰小时，用一个ķ我值分别为0.14和0.0056μM。在Sm ChiB – 6p共晶体结构中发现的化合物6p与Trp99和Trp220的强烈堆积相互作用证明了我们设计的可行性。我们的结果为开发有效的几丁质酶抑制剂用于病原体和害虫控制提供了新的见解。
• [EN] NOVEL ARGINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS D'ARGINASE
  申请人：UNIV GRONINGEN

  公开号：WO2020249821A1

  公开（公告）日：2020-12-17

  The present invention relates to novel arginase inhibitors of formula (I). These novel compounds are useful in the treatment of diseases that are associated with arginase activity, such as asthma, allergic rhinitis and COPD (chronic obstructive pulmonary disease).

  本发明涉及式(I)的新型精氨酸酶抑制剂。这些新型化合物在治疗与精氨酸酶活性相关的疾病方面具有用途，如哮喘、过敏性鼻炎和慢性阻塞性肺疾病（COPD）。
• Cinnamamide derivatives and drug compositions containing the same
  申请人：Tsumura & Co.

  公开号：US06413995B1

  公开（公告）日：2002-07-02

  The invention relates to cinnamamide derivatives having the following formula wherein R1 represents a hydroxyl group, a C1-6-alkoxy group, an arylalkoxy group or a substituted or unsubstituted amino group; R2 and R3 are same or different, each of which represents a hydrogen atom, a halogen atom or a C1-4-alkyl group; R4 represents a hydrogen atom or a C1-6-alkyl group; R5 represents a hydrogen atom, a C1-6-alkyl group or an aryl group; R6 represents a hydrogen atom, a C1-6-alkyl group, a cyano group or a C1-6-alkoxy-carbonyl group; W represents an oxygen atom, a sulfur atom, an imino group, a methylene group, a hydroxymethylene group or a carbonyl group; X and Y are same or different, each of which represents an oxygen atom or a sulfur atom; m represents an integer of 0 to 2; n represents an integer of 1 to 3; and when m is 0, a group: —C(R2)(R3)—W— may represent a vinylene group; or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the above compound, in particular, an immunomodulatory agent and a prophylactic or therapeutic agent for nephrotic syndrome, circulatory disorders or respiratory diseases.

  该发明涉及具有以下结构的肉桂酰胺衍生物，其中R1代表一个羟基、一个C1-6-烷氧基、一个芳基烷氧基或一个取代或未取代的氨基；R2和R3相同或不同，分别代表一个氢原子、一个卤原子或一个C1-4烷基基团；R4代表一个氢原子或一个C1-6烷基基团；R5代表一个氢原子、一个C1-6烷基基团或一个芳基；R6代表一个氢原子、一个C1-6烷基基团、一个氰基或一个C1-6烷氧羰基；W代表一个氧原子、一个硫原子、一个亚胺基、一个亚甲基基团、一个羟基亚甲基基团或一个羰基基团；X和Y相同或不同，分别代表一个氧原子或一个硫原子；m代表0到2之间的整数；n代表1到3之间的整数；当m为0时，一个基团：—C(R2)(R3)—W—可以表示一个乙烯基团；或其药学上可接受的盐；以及含有上述化合物的药物组合物，特别是一种免疫调节剂和一种肾病综合征、循环障碍或呼吸道疾病的预防或治疗剂。
• Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides
  作者：Pengtao Yuan、Xiangyu Gu、Xintong Ni、Yingxue Qi、Xusheng Shao、Xiaoyong Xu、Jianwen Liu、Xuhong Qian

  DOI：10.1016/j.bmcl.2021.128371

  日期：2021.11

  early clinical deterioration and high mortality. Recently, 2-aminoquinoline scaffold derivatives have shown pronounced activity in central nervous system disorders. We herein reported a series of 2-aminoquinoline-3-carboxamides as novel non-alkylator anti-glioblastoma agents. The synthesized compounds showed comparable activity to cisplatin against glioblastoma cell line U87 MG in vitro. Among them, we

  恶性胶质瘤是最常见的脑肿瘤，预后一般较差，临床恶化较早，死亡率较高。最近，2-氨基喹啉支架衍生物在中枢神经系统疾病中显示出显着的活性。我们在此报道了一系列 2-氨基喹啉-3-羧酰胺作为新型非烷化剂抗胶质母细胞瘤药物。合成的化合物在体外对胶质母细胞瘤细胞系 U87 MG 显示出与顺铂相当的活性。其中，我们发现6a对A172和U118 MG胶质母细胞瘤细胞系表现出良好的抑制活性，并通过流式细胞术分析诱导细胞周期停滞在G2/M期和U87 MG细胞凋亡。此外，6a对几种正常人细胞系显示出低细胞毒性。计算机研究表明，6a具有良好的理化特性，预计可以穿过血脑屏障。此外，还研究了初步的结构-活性关系，为进一步修饰这一系列化合物的更有效的试剂提供了启示。我们的研究结果表明，这种化合物具有作为抗胶质母细胞瘤药物的巨大潜力，在肿瘤细胞和非恶性细胞之间具有不同的作用。